Skip to main navigation Skip to search Skip to main content

Updated Results of TBCRC026: Phase II Trial Correlating Standardized Uptake Value With Pathological Complete Response to Pertuzumab and Trastuzumab in Breast Cancer

  • Roisin M. Connolly
  • , Jeffrey P. Leal
  • , Lilja Solnes
  • , Chiung Yu Huang
  • , Ashley Carpenter
  • , Katy Gaffney
  • , Vandana Abramson
  • , Lisa A. Carey
  • , Minetta C. Liu
  • , Mothaffar Rimawi
  • , Jennifer Specht
  • , Anna Maria Storniolo
  • , Vicente Valero
  • , Christos Vaklavas
  • , Ian E. Krop
  • , Eric P. Winer
  • , Melissa Camp
  • , Robert S. Miller
  • , Antonio C. Wolff
  • , Ashley Cimino-Mathews
    • Ben H. Park, Richard L. Wahl, Vered Stearns
  • Johns Hopkins University
  • Vanderbilt University
  • University of North Carolina at Chapel Hill
  • Mayo Clinic Rochester, MN
  • Baylor College of Medicine
  • University of Washington
  • Indiana University-Purdue University Indianapolis
  • University of Texas MD Anderson Cancer Center
  • University of Alabama at Birmingham
  • Dana-Farber Cancer Institute
  • Washington University St. Louis

Research output: Contribution to journal › Article › peer-review

Fingerprint

Dive into the research topics of 'Updated Results of TBCRC026: Phase II Trial Correlating Standardized Uptake Value With Pathological Complete Response to Pertuzumab and Trastuzumab in Breast Cancer'. Together they form a unique fingerprint.
Sort by

Medicine and Dentistry

Immunology and Microbiology